中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

87 records (took 0.026 seconds)

    IDENTIFICATION OF TUMOR-ASSOCIATED CELL SURFACE ANTIGENS FOR DIAGNOSIS AND THERAPY
    61.
    发明申请
    IDENTIFICATION OF TUMOR-ASSOCIATED CELL SURFACE ANTIGENS FOR DIAGNOSIS AND THERAPY 有权
    用于诊断和治疗的肿瘤相关细胞表面抗原的鉴定

    公开(公告)号：US20150376718A1

    公开(公告)日：2015-12-31

    申请号：US14830506

    申请日：2015-08-19

    Applicant: BioNTech AG

    Inventor： Özlem TÜRECI ,  Ugur SAHIN ,  Gerd HELFTENBEIN ,  Volker SCHLÜTER

    IPC: C12Q1/68

    CPC classification number: G01N33/57492 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/30 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2800/56

    Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.

    Abstract translation: 本发明提供具有肿瘤抑制活性的药剂，并且其对表达或异常表达肿瘤相关抗原的细胞是选择性的。 所述肿瘤相关抗原具有选自以下的核苷酸序列：（a）选自本文所述的特定序列的核苷酸序列或其6-50个连续核苷酸残基部分; （b）在严格条件下与具有（a）的核苷酸序列的核酸杂交的核酸的核苷酸序列; （c）相对于（a）或（b）的核苷酸序列退化的核苷酸序列; 和（d）与（a），（b）或（c）的核苷酸序列互补的核苷酸序列。 还提供了包含这些试剂的药物组合物和试剂盒，以及治疗，诊断或监测以肿瘤相关抗原的表达或异常表达为特征的疾病的方法。

    CLONAL EXPANSION OF B CELLS
    63.
    发明申请
    CLONAL EXPANSION OF B CELLS 有权
    B细胞的克隆扩增

    公开(公告)号：US20150099302A1

    公开(公告)日：2015-04-09

    申请号：US14571425

    申请日：2014-12-16

    Applicant: BioNTech AG ,  Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

    Inventor： Ugur Sahin ,  Ozlem Tureci ,  Torsten Seppmann ,  Holger Hoff ,  Jens Schumacher

    IPC: C07K14/705 ,  C12N5/0781 ,  C07K16/00

    CPC classification number: C07K14/70578 ,  C07K16/00 ,  C07K2319/30 ,  C12N5/0635

    Abstract: The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject.

    Abstract translation: 本发明提供重组蛋白，其包含CD40的细胞内节段的氨基酸序列和介导重组蛋白与免疫球蛋白重链的恒定区的缔合的氨基酸序列。 根据本发明的重组蛋白质可用于诱导具有预定抗原特异性的B细胞的克隆扩增，而不需要T细胞或CD40L介导的共刺激。 因此，本发明提供了用于针对感兴趣的抗原特异性的B细胞的克隆扩增的工具，以及产生分泌针对感兴趣的抗原的抗体的B细胞。 本发明的重组蛋白还可用于从人受试者的B细胞库中产生具有预定抗原特异性的完全人单克隆抗体。

    RECOMBINANT VACCINES AND USE THEREOF
    65.
    发明申请
    RECOMBINANT VACCINES AND USE THEREOF 审中-公开
    重组疫苗及其用途

    公开(公告)号：US20140134201A1

    公开(公告)日：2014-05-15

    申请号：US14152597

    申请日：2014-01-10

    Applicant: BioNTech AG

    Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sebastian Kreiter

    IPC: A61K47/48

    CPC classification number: A61K47/64 ,  A61K48/00 ,  C07K14/4748 ,  C07K14/70539 ,  C07K2319/02 ,  C07K2319/03

    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

    Abstract translation: 本发明涉及抗原的融合分子，其编码的核酸以及这种融合分子和核酸的使用。 特别地，本发明涉及融合分子，其包含MHC或SNARE分子的MHC分子和/或细胞质区域的抗原和跨膜区域和胞质区域。

    CYTOTOXIC IMMUNOSTIMULATING PARTICLES AND USES THEREOF
    68.
    发明申请
    CYTOTOXIC IMMUNOSTIMULATING PARTICLES AND USES THEREOF 有权

    公开(公告)号：US20210205447A1

    公开(公告)日：2021-07-08

    申请号：US17209926

    申请日：2021-03-23

    Applicant: BIONTECH AG

    Inventor： Steve PASCOLO

    IPC: A61K39/39

    Abstract: The present invention relates to particles comprising RNA, in which the RNA is associated with a cationic polymer or lipid or with both a cationic polymer and lipid, wherein the RNA comprises a cytotoxic nucleotide or cytotoxic nucleotide analog and/or the RNA is covalently attached to a cytotoxin, pharmaceutical compositions containing said particles and pharmaceutical uses of the particles and pharmaceutical compositions. The particles of the present invention are particularly useful as an immunostimulating medicament capable to block proliferation or induce death in dividing cells such as tumor cells.

Patent Agency Ranking